Shots:

• The advancement of BI 456906 to P-II study is based on the safety and tolerability and a wt. loss in individuals with a BMI up to 40 kg/m² - which will be a PBO controlled proof of concept study in patients with obesity and type 2 diabetes
• BI in-licensed two candidates from Zealand for GLP-1/glucagon dual agonist- Zealand will receive ~$21M out of ~$399M milestones at the initiation of P-II study with royalties on sales. For long-acting amylin analog- Zealand to receive ~$309M milestones and royalties on sales
• BI 456906 (qw) is dual-acting GLP-1/glucagon peptide- derived from the natural gut hormone oxyntomodulin activating both the GLP-1 and glucagon receptors and is a part of BI’s obesity and diabetes portfolio

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: Multivu